

## AMENDMENTS TO THE CLAIMS

1-7. (Canceled)

8. (Currently amended) A method of treating muscle hyperactivity, comprising administering a purified botulinum neurotoxin from a botulinum toxin complex, that is free from a-all non-toxic proteins in the complex, to a patient with muscle hyperactivity, wherein the time period to blockage of neurotransmission is shorter compared to the botulinum toxin complex, and wherein the botulinum neurotoxin is derived from one of botulinum toxin type A, B, C, D, E, or F.

9. (Previously Presented) The method of treatment according to claim 8, wherein the muscle hyperactivity is a disease that needs treatment with a fast acting remedy.

10. (Previously presented) The method of treatment according to claim 8, wherein the purified botulinum neurotoxin is administered in a composition that also comprises a botulinum neurotoxin-stabilizing substance other than the non-toxic protein of the botulinum toxin.

11. (Previously presented) The method of treatment according to claim 10, wherein the botulinum neurotoxin-stabilizing substance is human serum albumin.

12. (Canceled)

13. (Previously presented) The method of treatment according to claim 8, wherein the muscle hyperactivity is dystonia.

14. (Canceled)

15. (Previously presented) The method of treatment according to claim 9, wherein the muscle hyperactivity is systemic muscle hyperactivity.

16. (Previously presented) The method of treatment according to claim 15, wherein the systemic muscle hyperactivity is generalized dystonia or systemic spasticity.